Drug-drug interactions among elderly patients hospitalized for drug toxicity.

By D. Juurlink, M. Mamdani, A. Kopp, A. Laupacis, Donald A. Redelmeier. Journal of the American Medical Association (JAMA), 2003

782 citations recorded by the source corpus.

Subfields: Geriatrics and Gerontology, Pharmacology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/8255cd645998f23256d1ab838141f28f6392473b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Geriatrics and Gerontology

1. L. Fried

In Pharmacology

1. Fei Wang
2. Ping Zhang
3. Jianying Hu
4. Anita M. Preininger

Citations in the corpus

• Pharmaceuticals and Personal Care Products in the Environment: What Are the Big Questions? (2012, background): “1224 volume 120 | number 9 | September 2012 • Environmental Health Perspectives Many pharmaceuticals, if consumed together at therapeutic doses, can cause severe adverse inter actions in humans (e.g., Juurlink et al. 2003).”
• Pharmaceuticals and personal care products in the aquatic environment in China: a review. (2013, background): “[193] found that sever interactions in human can be observed if one consumed pharmaceuticals together at therapeutic dose.”
• Molecular Systems Biology Peer Review Process File Indi: a Computational Framework for Inferring Drug Interactions and Their Associated Recommendations Transaction Report (neutral): “Moreover, certain patient groups (e.g., elderly patients (Bergendal et al, 1995; Juurlink et al, 2003; Doubova Dubova et al, 2007) or cancer patients (Riechelmann et al, 2007)) are typically administered numerous medications, exposing them to a high risk of multiple interactions.”
• Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. (2005, methodology): “When we developed a treatment plan for a hypothetical patient using a conservative regimen created in accordance with CPGs, she was treated with multiple medications with high complexity, with the attendant risks of medication errors, adverse drug events, drug interactions, and hospitalization.(4,58”
• Label Propagation Prediction of Drug-Drug Interactions Based on Clinical Side Effects (2015, methodology): “(2) Clinical phenotypic information is derived from direct observations from human, thus has better translational power when comparing with molecular or animal models19 in DDI predictions.”
• Clinical consequences of polypharmacy in elderly (2014, background): “Drug--drug interactions are a frequent cause of preventable ADEs and medication-related hospitalizations [18,22].”
• Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. (2009, positive): “6-fold increased risk of hypoglycemia (32), and case reports of extreme hypoglycemia have been reported.”